Teva Pharmaceutical Industries Limited TEVA
Set alert
At close · Oct 30
After hours · Oct 30, 7:23 PM ET
- YTD
- +34.86%
- 1 year
- +110.13%
- Open
- 41.17
- Prev close
- 41.47
- Mkt cap
- 49.09B
- Vol
- 7.36M
- Avg vol
- 5.49M
- EPS
- 0.60
- P/E
- 70.15
- Div yield
- 0.00%
More statistics
- Low
- 41.22
- High
- 42.59
- Forward P/E
- 13.58
- Beta
- 0.82
- Short ratio
- 4.40
- Inst. own
- 29.68%
- Dividend
- 0.00
- Ex-div date
- Nov 27, 2017
- Earnings
- Nov 3, 2026
- 50-d avg
- 38.98
- 200-d avg
- 34.53
- 1y target
- 47.58
5D chart
Signals (117)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:55 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:35 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:30 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:25 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:05 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:05 PM | 1 day ago |
| RSI: Oversold | Oct 30, 2:50 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:10 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 2:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:00 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:40 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:35 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:25 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:10 PM | 1 day ago |
| SMA: Bearish | Oct 30, 11:30 AM | 1 day ago |
| SMA: Bullish | Oct 30, 11:25 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:20 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:10 AM | 1 day ago |
| SMA: Bullish | Oct 30, 11:05 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:25 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:30 PM | 2 days ago |
| RSI: Overbought | Oct 29, 1:30 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:55 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:35 PM | 4 days ago |
| RSI: Overbought | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:55 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 12:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 6 days ago |
News
1 day ago seekingalpha.com
Teva: I Still See Upside After A Massive Rally
Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals, with a robust new product pipeline. FDA approval of WELTRUZA and…
1 day ago fool.com
Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?
Teva's pivot from generic drugs to branded drugs has fueled an 100% surge for shares over the past year. Based on recent results and catalysts, don't rule out a continued, steady move towards higher…
3 days ago zacks.com
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and…
-
5 days ago benzinga.com
Teva Pharmaceuticals International GmbH Acquires BioXcel Therapeutics' Assets For $57.5M Upfront Payment
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it has completed the acquisition of assets from BioXcel…
5 days ago globenewswire.com
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review
6 days ago seekingalpha.com
Baron Health Care Fund Q3 2026 Top Contributors And Detractors
TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA…
-
1 week ago benzinga.com
Teva Pharma And Sanofi Report Duvakitug Maintained Efficacy Through 44 Weeks In Ulcerative Colitis And Crohn's Disease
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response,…
-
2 weeks ago benzinga.com
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47
Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $47.
3 weeks ago benzinga.com
FDA Approves Teva's New Once-Monthly Schizophrenia Injection
FDA approves Teva's Weltruza, a once-monthly injectable for adults with schizophrenia, eliminating the need for daily oral medication.
-
3 weeks ago benzinga.com
Teva Pharmaceuticals Receives FDA Approval Of WELTRUZA For Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults
WELTRUZA clinical trial results demonstrated improvement in symptoms (PANSS), significant reduction in illness severity (CGI-S), as well as improvement in personal and social functioning (PSP).1 In…
-
1 month ago benzinga.com
Teva Pharma Presents New Ecopipam Data Highlighting Potential Benefits For Pediatric Tourette Syndrome Patients At MDS 2026
Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipamAn interim 18-month analysis of an ongoing…
-
1 month ago benzinga.com
Teva Pharma Says Journal Of Child Neurology Publishes Comprehensive Review Examining Dopamine Pathways In Tourette Syndrome And Therapeutic Potential Of Ecopipam For Treatment Of Pediatric Patients With Tourette Syndrome
The published review examines dopamine’s role in tic generation and how approved and investigational drugs may affect dopamine to reduce tics as well as synthesizes clinical trial evidence that…
1 month ago benzinga.com
This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with price targets of $70, $159, $42, $55 and $30.
-
1 month ago benzinga.com
TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55
TD Cowen initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $55.
-
1 month ago benzinga.com
Teva Pharmaceutical Industries Receives FDA Approval For DEGEVMA To Treat Bone Complications In Patients With Advanced Cancer
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA™ (denosumab-adet) as a biosimilar to Xgeva®…
-
1 month ago benzinga.com
Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50
Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $50.
-
1 month ago benzinga.com
Teva Pharmaceuticals Presents Data Showing Healthcare Providers Prioritize Drowsiness Risk, Long-Term Response And Drug Interactions When Treating Older TD Patients
New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for…
-
1 month ago benzinga.com
Teva Pharmaceuticals Presents Data Showing UZEDY Improves Treatment Continuity, Reduces Hospitalizations And Cuts Healthcare Costs In Schizophrenia And Bipolar I Disorder
New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I)The new real-world…
-
1 month ago benzinga.com
Teva Presents New SOLARIS Data Showing TEV-'749 Maintained Schizophrenia Stabilization And Supported Remission In Long-Term Use
In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of…
-
1 month ago benzinga.com
Roche Receives EMA CHMP Recommendation Of Approval Ocrevus For Pediatric Patients With Relapsing Forms Of Multiple Sclerosis
The U.S. FDA approved Ocrevus for paediatric RMS patients in May 2026. A final decision from the European Commission is expected in the near future."Children and teens living with multiple sclerosis…
1 month ago benzinga.com
Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed
Teva Pharmaceutical Industries had a busy week that included a major debt refinancing, a NYSE trading shift and analyst activity.
-
1 month ago benzinga.com
Teva Priced Approximately $4.9B (Equivalent) of Senior Notes
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the "Notes").…
-
1 month ago benzinga.com
Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45
Leerink Partners analyst Daniel Clark initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $45.
-
1 month ago benzinga.com
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48
UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $42 to $48.
2 months ago benzinga.com
Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study
Teva reports positive Phase 2a results for TEV '408, successfully preventing gluten-induced intestinal damage in adult celiac patients.
-
2 months ago benzinga.com
Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study
Teva Pharma is trading higher after announcing positive topline results from a Phase 2a study of TEV '408, which met its primary endpoint.
-
2 months ago benzinga.com
Teva Says Topline Results From Ongoing Phase 2a Study Of TEV ‘408 For Celiac Disease Met Its Primary Endpoint, Demonstrating Statistically Significant And Clinically Meaningful Prevention Of Gluten-induced Intestinal Damage Versus Placebo At Week 8
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced positive topline results from an ongoing Phase 2a study of TEV ‘408, an investigational anti-interleukin-15 monoclonal…
2 months ago benzinga.com
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
-
2 months ago benzinga.com
Teva And Trump Administration Commit To Lowering Select Medicaid Drug Costs
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select…
-
2 months ago benzinga.com
Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms
https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-with-nine-additional-pharmaceutical-manufacturers-to-lower-drug-prices-for-americans/
2 months ago benzinga.com
BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid
BioXcel Chapter 11 sends BTAI shares sharply lower as Teva becomes the stalking horse bidder for IGALMI and BXCL501 assets.
2 months ago benzinga.com
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.
-
2 months ago benzinga.com
Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva…
-
2 months ago benzinga.com
Teva Pharmaceuticals' New Drug Application For Ecopipam Gets FDA Acceptance To Treat Pediatric Patients With Tourette Syndrome
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application…
-
2 months ago benzinga.com
Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $42
Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $40 to $42.
3 months ago benzinga.com
Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing
Teva revenue tops estimates despite an earnings miss. The company raises 2026 sales guidance and highlights strong brand growth.
-
3 months ago benzinga.com
Teva Pharmaceutical Indus Lowers FY2026 Adj EPS Guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 Est; Raises FY2026 Sales Guidance from $16.400B-$16.800B to $16.500B-$16.850B vs $16.618B Est
Teva Pharmaceutical Indus (NYSE:TEVA) lowers FY2026 Adj EPS guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 analyst estimate. Raises FY2026 sales outlook from $16.400 billion-$16.800 billion to…
-
3 months ago benzinga.com
Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B Estimate
Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.25 by 92 percent. This is a 96.97 percent decrease over earnings…
-
3 months ago benzinga.com
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44
Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $44.
-
3 months ago benzinga.com
Teva Pharmaceuticals International Granted Exclusive Rights To Commercialize Formulations For Polpharma Biologics’ Proposed Biosimilar To Ocrevus
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE:AND) and Polpharma Biologics International AG today announced a global licensing agreement granting…
-
3 months ago benzinga.com
Teva Pharma And Polpharma Biologics Announce Global Licensing Agreement Granting Teva Exclusive Rights To Commercialize Both Formulations Of Polpharma Biologics’ Proposed Biosimilar To Ocrevus, Upon Regulatory Approval
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances…
-
3 months ago benzinga.com
Teva Pharmaceutical Industries And Samsung Bioepis Partner To Commercialize OPUVIZ Aflibercept Biosimilar In Canada
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that the companies have entered into a license and commercialization agreement for OPUVIZ®…
3 months ago benzinga.com
Bill Ackman Says Next $1 Trillion Company Will Come From Israel – ‘Imagine if Silicon Valley Was a Country’
Bill Ackman is bullish on Israel. Here's why he thinks investors should watch the region.
3 months ago benzinga.com
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial
Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.
-
3 months ago benzinga.com
Teva Shared Data From Ongoing Phase 1b Study Of TEV-’408 Showing Improvements In Skin Pigmentation In Active Or Stable Non-Segmental Vitiligo Patients; Plans To Advance TEV-’408 Into Phase 2b Study In Vitiligo In Q4 2026
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to advance its TEV-’408, an investigational anti-interleukin-15 monoclonal antibody, into a Phase 2b study in vitiligo…
-
4 months ago benzinga.com
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose
https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose
-
4 months ago benzinga.com
Teva Pharma Announces New Data Highlighting Comprehensive Tardive Dyskinesia Symptom Improvement From Treatment With AUSTEDO And AUSTEDO XR
New analysis from the IMPACT-TD Registry demonstrates that treatment with AUSTEDO and AUSTEDO XR led to reductions in Abnormal Involuntary Movement Scale (AIMS) scores in all participants, which were…
4 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
-
4 months ago benzinga.com
Teva Pharma Announces New Data From Real-World, Decentralized Study Demonstrating AUSTEDO Improves Quality Of Life In HD's Chorea Patients And Caregivers
New real-world survey data reveal the daily impact of Huntington's disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of…
-
5 months ago benzinga.com
Teva Pharmaceutical Industries Introduces AHZANTIVE In Europe To Expand Footprint In Ophthalmology
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea®, in Europe further strengthening the Company's growing